TFPI

TFPI Full Name

tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor)

TFPI Introduction

The TFPI (Tissue Factor Pathway Inhibitor) gene encodes a critical serine protease inhibitor that serves as the primary physiological regulator of the tissue factor (TF)-dependent pathway of blood coagulation. Also known by several synonyms including lipoprotein-associated coagulation inhibitor (LACI) and extrinsic pathway inhibitor (EPI), TFPI is a multivalent Kunitz-type inhibitor that controls the initiation phase of the coagulation cascade. By forming an inhibitory quaternary complex with factor Xa and the factor VIIa-tissue factor complex, TFPI provides a natural anticoagulant barrier that prevents excessive thrombus formation following vascular injury. Beyond its classical role in hemostasis, TFPI has emerged as a multifunctional protein involved in smooth muscle cell proliferation, angiogenesis, and embryonic development, with growing clinical significance in hemophilia management, cardiovascular disease, and inflammation.

Figure 1. Strcuture of TFPI.

Genomic Characteristics
The human TFPI gene is located on chromosome 2 at position 2q32.1 and spans approximately 35 kilobases of genomic DNA. The gene contains multiple exons that encode a protein-coding transcript producing the full-length tissue factor pathway inhibitor protein of 304 amino acids. The primary translation product includes a 28-amino acid signal peptide that directs the protein to the secretory pathway, resulting in a mature protein of approximately 35 kDa. Several transcript variants generated through alternative splicing have been identified, producing protein isoforms that differ in their inhibitory activity, specificity, and cellular localization. The gene exhibits broad evolutionary conservation, with clear orthologs identified in mouse (Tfpi), rat (Tfpi), zebrafish (tfpia), and even distantly related species including Caenorhabditis elegans, reflecting the fundamental importance of coagulation regulation across phylogeny.

Molecular Function and Mechanism of Action
TFPI functions as the primary physiological inhibitor of the tissue factor-initiated coagulation pathway, operating through a two-step inhibitory mechanism. Coagulation is initiated when vascular injury exposes tissue factor to circulating blood, allowing formation of the factor VIIa-TF complex, which activates factors IX and X. TFPI exerts its regulatory function by first binding and inhibiting factor Xa through its K2 domain. The resulting Xa-TFPI complex then binds with high affinity to the VIIa-TF complex via the K1 domain, forming a stable quaternary Xa-TFPI-VIIa-TF complex that effectively shuts down further protease activation. This inhibitory mechanism creates an autoregulatory loop that controls the initial burst of thrombin generation. The C-terminal basic region of TFPI is required for rapid physiological inhibition, and its absence results in significantly reduced anticoagulant activity. Beyond its role in coagulation, TFPI also inhibits smooth muscle cell proliferation through its C-terminal domain, and endothelium-bound TFPI contributes to the antithrombotic potential of the vascular surface.

Alternate Names for TFPI

TFPI; tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor); EPI; TFI; LACI; TFPI1; tissue factor pathway inhibitor; anti-convertin; extrinsic pathway inhibitor;